Don't jump in without doing some research first.
As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.
MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.
Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?
/CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression....